Core Points - The company will present preclinical data on the oral, highly potent pan-KRAS inhibitor JAB-23E73 at the 2025 AACR-NCI-EORTC meeting in Boston from October 22 to October 26, 2025 [1] - The abstract for JAB-23E73 will be released on October 22, 2025, and will also be published as free supplementary content in the journal Molecular Cancer Therapeutics [1] - The poster presentation for JAB-23E73 is scheduled for October 23, 2025 [1] Drug Characteristics - JAB-23E73 exhibits excellent antitumor activity across various cancer types with different KRAS driver mutations or amplifications [2] - In mouse tumor models driven by KRAS, JAB-23E73 effectively induces tumor regression without significant weight changes, indicating good tolerability and a wide therapeutic window [2] - The drug has favorable pharmacokinetic properties for oral administration and regulates the inhibition of p-ERK in tumors based on its plasma concentration [2] Clinical Trials - Phase I clinical trials for JAB-23E73 targeting advanced solid tumors with KRAS gene mutations are currently underway in China and the United States [2]
加科思-B在2025年AACR-NCI-EORTC国际分子靶点与癌症治疗学会议上展示 Pan-KRAS抑制剂JAB-23E73的临床前数据